FEDERAL COURT OF AUSTRALIA
Apotex Pty Ltd v Les Laboratoires Servier (No 3)
[2014] FCA 1029
Citation: Apotex Pty Ltd v Les Laboratoires Servier (No 3) [2014] FCA 1029 Parties: APOTEX PTY LTD ACN 096 916 148 v LES LABORATOIRES SERVIER and SERVIER LABORATORIES (AUST) PTY LTD; ACTAVIS PTY LIMITED File number: NSD 51 of 2012 Judge: RARES J Date of judgment: 26 August 2014 Legislation: Patents Act 1990 (Cth)
Federal Court Rules 2011 (Cth)Cases cited: Apotex Pty Ltd v Les Laboratoires Servier (No 2) [2014] FCA 751 referred to
Apotex Pty Ltd v Les Laboratories Servier [2013] FCA 1426 applied
Bayer Pharma AG v General Health Pty Ltd (2012) 99 IPR 59 applied
CSL Ltd v Novo Nordisk Pharmaceuticals Pty Ltd (No 2) (2010) 190 FCR 522 referred to
Owners of the Ship “Shin Kobe Maru” v Empire Shipping Company (Inc) (1994) 181 CLR 404 appliedDate of hearing: 26 August 2014 Place: Sydney Division: GENERAL DIVISION Category: No catchwords Number of paragraphs: 16 Counsel for the Applicant: Mr D K Catterns QC with Mr N R Murray Solicitor for the Applicant: Herbert Smith Freehills Counsel for the Respondents: Mr C Dimitriadis Solicitor for the Respondents: Allens Counsel for the Opponent: Mr J S Cooke Solicitor for the Opponent: Ashurst
IN THE FEDERAL COURT OF AUSTRALIA
NEW SOUTH WALES DISTRICT REGISTRY
GENERAL DIVISION
NSD 51 of 2012
BETWEEN: APOTEX PTY LTD ACN 096 916 148
ApplicantAND: LES LABORATOIRES SERVIER
First RespondentSERVIER LABORATORIES (AUST) PTY LTD
Second RespondentACTAVIS PTY LIMITED
Opponent
JUDGE:
RARES J
DATE:
26 AUGUST 2014
PLACE:
SYDNEY
REASONS FOR JUDGMENT
(REVISED FROM THE TRANSCRIPT)
The present stage of the dispute in these proceedings, in relation to Servier’s application to amend under s 105 of the Patents Act 1990 (Cth), concerns the material that Servier can be required to produce under notices to produce proposed to be issued by Apotex and Actavis, as a party that has appeared under r 34.41(3) of the Federal Court Rules 2011 (Cth). That application seeks to amend the complete specification of the patent to insert descriptions of the 1986 and 1991 methods of salification that I found, in the context of the pleaded issues in the revocation and infringement proceeding, to have been the best method of performing the invention known to Servier that the complete specification had failed to disclose: see my reasons in Apotex Pty Ltd v Les Laboratories Servier [2013] FCA 1426 and Apotex Pty Ltd v Les Laboratoires Servier (No 2) [2014] FCA 751.
Background
The proposed notices to produce, as refined during the course of argument, seek documents that Servier should be able to assemble and produce without undue difficulty relating to any method or methods that it used to produce perindropril arginine that are referred to in a number of identified documents. The purpose for which Apotex and Actavis seek that material is to enable them to advance argument, as a foundation for the refusal of relief under s 105(1), that,…
Keep reading for free
Create a free CaseChat account to read Apotex Pty Ltd v Les Laboratoires Servier (No 3) and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2014] FCA 1029
- Decision Date
CaseChat Overview and Summary
The court ordered that the limited notices to produce be issued and answered, subject to any proper objection.
Orders
Orders of the court
Full text does not contain this section.
Background
Background to the litigation
Evidence
Evidence Before The Court
Full text does not contain this section.
Decision
Reasons for decision
Full text does not contain this section.
Ratio Decidendi
Legal Principle Established
Moreover, Actavis argued that, as a person given a right to be heard, it is not bound by whatever findings were made earlier in the proceedings and it can challenge, in any way it sees fit, the fullness and frankness of Servier’s disclosure of, at least for present purposes, the best method in the complete specification of the patent.Consideration The present interlocutory dispute is not the appropriate place to determine which of the parties’ contentions should prevail. The proceedings are attended by the complexity that the way in which Apotex set out to prove that Servier had failed to disclose the best method known to it was deliberately limited and confined to that which Apotex established at the trial and is reflected in the declarations. Ordinarily, parties are bound by the way in which they conduct their case. The issues that will flow from how Apotex chose to conduct the case at trial will need to be determined in light of the facts advanced at the hearing of the amendment application. The powers to grant an amendment under s 105(1) and to revoke a patent under s 138(3) involve the exercise of a judicial discretion that is apparently unconfined. It is quite inappropriate to read such provisions by making implications or imposing limitations that are not found in the express words of the statutory provision: Owners of the Ship “Shin Kobe Maru” v Empire Shipping Company Inc (1994) 181 CLR 404 at 421 per Mason CJ, Brennan, Deane, Dawson, Toohey, Gaudron and McHugh JJ and Apotex [2013] FCA 1426 at [202]-[204]. A patentee seeking a favourable exercise of the discretion under s 105 should give full disclosure of all relevant matters bearing on the exercise of the discretion, as Yates J held in Bayer Pharma AG v General Health Pty Ltd (2012) 99 IPR 59 at 88 [164]; see also CSL Ltd v Novo Nordisk Pharmaceuticals Pty Ltd (No 2) (2010) 190 FCR 522 at 539 [56] per Jessup J. Accordingly, I think that for the purposes of enabling the evidentiary picture that each party wishes to have available to it to present a case on the amendment application, I should allow the limited notices to produce to be issued and require them to be answered, subject to any proper objection. Whether what is produced by those notices will or can be relied on by Apotex and/or Actavis and the extent to which that reliance may affect the maintenance of the hearing dates for the amendment application fixed for 27 October 2014 will need to be considered if, and once, Apotex and Actavis identify any relevant other method of performing the invention that they allege was known to Servier at a relevant time and how either of them seeks to prove that that method is a better method than the ones the subject of the declaration. There may or may not be substance, at that time, revealed in Servier’s current apprehension that a great deal of work may be necessary in order to meet such an assertion, including the need to conduct experiments. Apotex takes issue with whether Servier’s apprehension is relevant or well-founded.